2. Search Result
Search Result
Results for "

fibroblast activation

" in MedChemExpress (MCE) Product Catalog:

189

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dyes

5

Biochemical Assay Reagents

24

Peptides

10

Inhibitory Antibodies

19

Natural
Products

7

Isotope-Labeled Compounds

6

Antibodies

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116084
    Trimethylamine N-oxide
    Maximum Cited Publications
    11 Publications Verification

    		 Drug Metabolite NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine N-oxide
  • HY-B0636
    Triamcinolone acetonide
    5+ Cited Publications

    		 Glucocorticoid Receptor FGFR Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide activates macrophage with anti-inflammatory characteristics. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis .
    Triamcinolone acetonide
  • HY-128643
    FAPI-4
    30+ Cited Publications

    		 FAP Cancer
    FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. 68Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .
    FAPI-4
  • HY-137331
    FAPI-46
    2 Publications Verification

    		 FAP Cancer
    FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with 68Ga or 177Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .
    FAPI-46
  • HY-100684
    UAMC-1110
    2 Publications Verification

    		 Prolyl Endopeptidase (PREP) FAP Cancer
    UAMC-1110 is a highly potent and selective inhibitor of fibroblast activation protein (FAP) with an IC50 of 3.2 nM. UAMC-1110 also inhibits prolyl oligopeptidase (PREP) with an IC50 of 1.8 μM .
    UAMC-1110
  • HY-P99269
    Sibrotuzumab
    1 Publications Verification

    BIBH 1; Anti-Human FAP Recombinant Antibody

    		 FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-147173
    FAPI-74

    		FAP Cancer
    FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .
    FAPI-74
  • HY-47979
    FAP-IN-2
    1 Publications Verification

    		 FAP Cancer
    FAP-IN-2 is an isonitrile-containing fibroblast activation protein (FAP) inhibitor. FAP-IN-2 can be labeled with technetium-99m ( 99mTc) for targeted tumor SPECT imaging .
    FAP-IN-2
  • HY-145938
    OncoFAP

    		FAP Cancer
    OncoFAP is an ultra-high-affinity ligand of fibroblast activation protein (FAP) for targeting applications with pan-tumoral potential.
    OncoFAP
  • HY-136641
    NOTA-FAPI

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    NOTA-FAPI is a fibroblast activation protein (FAP) inhibitor. NOTA-FAPI can be used as a probe for FAP-targeted tumour imaging. NOTA-FAPI has good tumour detection efficacy and excellent imaging quality .
    NOTA-FAPI
  • HY-108915
    Trimethylamine N-oxide dihydrate
    Maximum Cited Publications
    11 Publications Verification

    		 NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Trimethylamine N-oxide dihydrate is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide dihydrate induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide dihydrate also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine N-oxide dihydrate
  • HY-116084S
    Trimethylamine N-oxide-d9
    1 Publications Verification

    		 NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Trimethylamine N-oxide-d9 is the deuterium labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine N-oxide-d9
  • HY-P10944
    Unlabeled FXX489

    NNS309

    		 FAP Inflammation/Immunology Cancer
    Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with 68Ga and 177Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .
    Unlabeled FXX489
  • HY-145983
    Suc-Gly-Pro-AMC
    1 Publications Verification

    		 FAP Prolyl Endopeptidase (PREP) Cancer
    Suc-Gly-Pro-AMC is a fluorescent substrate. Suc-Gly-Pro-AMC is a fibroblast activation protein (FAP) specific substrate. Suc-Gly-Pro-AMC reacts with recombinant porcine prolyl oligopeptidase. Suc-Gly-Pro-AMC can be used to study the activity of FAP, prolyl endopeptidase (PREP). Suc-Gly-Pro-AMC is used in glioma research .
    Suc-Gly-Pro-AMC
  • HY-P10945
    FAP targeting peptide for FXX489

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAP targeting peptide for FXX489 is the polypeptide part of Unlabeled FXX489 (HY-P10944). Unlabeled FXX489 is a fibroblast activation protein (FAP)-targeting ligand .
    FAP targeting peptide for FXX489
  • HY-P99010
    Bemarituzumab

    		FGFR Cancer
    Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer .
    Bemarituzumab
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-153552A
    NH2-UAMC1110 TFA

    		FAP Cancer
    NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
    NH2-UAMC1110 TFA
  • HY-175739
    TFAM activator 1

    		Mitochondrial Metabolism CXCR Neurological Disease Metabolic Disease Inflammation/Immunology
    TFAM activator 1 is a TFAM activator. TFAM activator 1 increases TFAM protein levels, promotes mitochondrial DNA stability, increases mitochondrial DNA copy number, and prevents mitochondrial DNA from escaping into the cytoplasm. TFAM activator 1 improves cellular energy metabolism in cybrid cells. TFAM activator 1 reduces fibrosis markers in fibroblasts. TFAM activator 1 can be used in the research of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes syndrome, systemic sclerosis, and autoimmune diseases .
    TFAM activator 1
  • HY-P99614
    Fazpilodemab

    BFKB8488A; RG-7992; RO-7040551

    		 FGFR Metabolic Disease
    Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
    Fazpilodemab
  • HY-P3281
    FGL peptide

    		FGFR Neurological Disease
    FGL peptide is a fibroblast growth factor receptor (FGFR) modulator and blood-brain barrier-penetrant. FGL peptide activates NCAM-FGFR and FGFR1 signaling pathways. FGL peptide alters expression of apoptosis, signal transduction and metabolism regulator genes in traumatic brain injury contexts. FGL peptide can be used for the research of traumatic brain injury .
    FGL peptide
  • HY-P99902
    Simlukafusp alfa

    FAP-IL2v; RO6874281; RG7461

    		 Interleukin Related Cancer
    Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
    Simlukafusp alfa
  • HY-148127
    TAM558

    		Drug-Linker Conjugates for ADC Cancer
    TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
    TAM558
  • HY-148859
    AA-T3A-C12
    1 Publications Verification

    		 Liposome Metabolic Disease Inflammation/Immunology
    AA-T3A-C12 is an anisamide ligand-tethered lipidoid (AA-lipidoid). AA-T3A-C12 mediates great RNA delivery and transfection of activated fibroblasts .
    AA-T3A-C12
  • HY-N7259
    (+)-Isomenthone

    		JNK p38 MAPK Apoptosis Inflammation/Immunology
    (+)-Isomenthone is an enantiomer form of Menthone (HY-N2381). (+)-Isomenthone blocks TNF-α-triggered activation of the JNK and p38 MAPK pathways.(+)-Isomenthone inhibits TNF-α-mediated reductions in cell viability, increases in apoptosis, and downstream apoptotic events linked to pathway activation.(+)-Isomenthone protects human dermal fibroblasts against TNF-α-induced cell death under serum-deprived conditions .
    (+)-Isomenthone
  • HY-125366
    ARI-3099

    		FAP Metabolic Disease
    ARI-3099 is an oral fibroblast activation protein (FAP) inhibitor. ARI-3099 specifically inhibits the proteolytic activity of FAP and blocks the cleavage of human FGF-21 between residues P171 and S172. ARI-3099 extends the half-life of circulating human FGF-21 in mice. ARI-3099 can be used in the research of type 2 diabetes and metabolic disorders .
    ARI-3099
  • HY-133961
    Cholesterol β-D-glucoside

    Cholesteryl glucoside

    		 HSP Metabolic Disease
    Cholesterol β-D-glucoside (Cholesteryl glucoside) is a heat shock transcription factor 1 (HSF1) activator. Cholesterol β-D-glucoside induces HSP70 in fibroblast cells .
    Cholesterol β-D-glucoside
  • HY-160289
    ARI-3144

    		FAP Cancer
    ARI-3144 is an excellent and specific substrate for fibroblast activation protein (FAP). ARI-3144 is usually coupled with the fluorophore 7-Amino-4-methylcoumarin (HY-D0027) (AMC) for detection and quantification of FAP .
    ARI-3144
  • HY-162334
    HYOU1-IN-1

    		HSP Inflammation/Immunology Cancer
    HYOU1-IN-1 (Compound 33) is an inhibitor of hypoxia-upregulated protein 1 (HYOU1) with anti-inflammatory activity. HYOU1-IN-1 can be used in research on the regulation of fibroblast activation, chronic inflammation, and fibrotic diseases .
    HYOU1-IN-1
  • HY-161074
    PNT6555

    		FAP Cancer
    PNT6555 is a fibroblast activation protein-α (FAP) inhibitor. PNT6555 has antitumor activity. PNT6555 can be used for imaging of FAP-positive tumors .
    PNT6555
  • HY-P3441A
    3BP-4089 TFA

    		FAP Cancer
    3BP-4089 TFA is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 TFA is often conjugated with radionuclides for tumor diagnosis and research .
    3BP-4089 TFA
  • HY-W404002
    BR102910

    		Prolyl Endopeptidase (PREP) Metabolic Disease
    BR102910 is a selective fibroblast activation protein (FAP) inhibitor with the IC50 of 2 nM. BR102910 also inhibits prolyl oligopeptidase (PREP) with the IC50 of 49.00 μM. BR102910 can be used for the researchof type 2
    BR102910
  • HY-77278
    25-Hydroxytachysterol3

    		VD/VDR Aryl Hydrocarbon Receptor LXR PPAR Others
    25-Hydroxytachysterol3 is the metabolite of Vitamin D3 (HY-15398). 25-Hydroxytachysterol3 inhibits the proliferation of epidermal keratinocytes and dermal fibroblasts, stimulates the expression of differentiation- and antioxidant-related genes in keratinocytes. 25-Hydroxytachysterol3 activates vitamin D receptor (VDR) and aryl hydrocarbon receptor (AhR), liver X receptor α/β (LXR α/β) and peroxisome proliferator-activated receptor γ (PPARγ), stimulates the expression of CYP24A1 .
    25-Hydroxytachysterol3
  • HY-160426
    Gcase activator 3

    		Glycosidase Neurological Disease
    Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies .
    Gcase activator 3
  • HY-N0671R
    Rhapontin (Standard)
    2 Publications Verification

    Rhaponiticin (Standard)

    		 Reference Standards Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin (Standard)
  • HY-177459
    DOTA-2P(FAPI)2

    		FAP Cancer
    DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .
    DOTA-2P(FAPI)2
  • HY-P3441
    3BP-4089

    		FAP Cancer
    3BP-4089 is a highly efficient fibroblast activation protein (FAP) targeting peptide. 3BP-4089 is often conjugated with radionuclides for tumor diagnosis and research .
    3BP-4089
  • HY-176958
    OncoFAP-EN-DOTAGA

    		FAP Others
    OncoFAP-EN-DOTAGA is a FAP (fibroblast activation protein) targeting conjugate compound. OncoFAP-EN-DOTAGA can chelate radioactive isotopes (such as ) Ga-68 or fluorescent agent and can be used as a probe with targeting binding functions .
    OncoFAP-EN-DOTAGA
  • HY-177083
    Faridoxorubicin

    AVA-6000

    		 FAP Cancer
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis) .
    Faridoxorubicin
  • HY-116084S1
    Trimethylamine-N-oxide-13C3

    		Isotope-Labeled Compounds NOD-like Receptor (NLR) Reactive Oxygen Species (ROS) TGF-beta/Smad Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Trimethylamine-N-oxide- 13C3 is the 13C-labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway .
    Trimethylamine-N-oxide-13C3
  • HY-164725
    FAPI-mFS

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-149860
    FAP-IN-1

    		FAP Cancer
    FAP-IN-1 is a fibroblast activation protein (FAP) inhibitor with an IC50 value of 3.3 nM. FAP-IN-1 can be used for the research of cancer .
    FAP-IN-1
  • HY-147057A
    Rofapitide tetraxetan acetate

    FAP-2286 acetate

    		 FAP Cancer
    Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .
    Rofapitide tetraxetan acetate
  • HY-W668749
    3BP-3580

    		FAP Cancer
    3BP-3580 is a fibroblast activation protein (FAP) inhibitor (pIC50: 8.6), and can be used for cancer research .
    3BP-3580
  • HY-47979A
    FAP-IN-2 TFA
    1 Publications Verification

    		 FAP Cancer
    FAP-IN-2 TFA is an isonitrile-containing fibroblast activation protein (FAP) inhibitor. FAP-IN-2 TFA can be labeled with technetium-99m ( 99mTc) for targeted tumor SPECT imaging .
    FAP-IN-2 TFA
  • HY-D2281
    FAP Ligand 2

    		FAP Cancer
    FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging .
    FAP Ligand 2
  • HY-175322
    FAPI-P8PN

    		FAP Cancer
    FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors .
    FAPI-P8PN
  • HY-175353
    TriOncoFAP-GlyPro-MMAE

    		FAP Cancer
    TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC50 of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE) .
    TriOncoFAP-GlyPro-MMAE
  • HY-145358
    FAP-PI3KI1

    		PI3K Cancer
    FAP-PI3KI1 is a fibroblast-activated protein (FAP)-targeted PI3K inhibitor that selectively targets FAP-expressing human idiopathic pulmonary fibrosis (IPF) cells and effectively inhibits collagen synthesis and reduces collagen deposition .
    FAP-PI3KI1
  • HY-128642
    FAPI-2

    		FAP Cancer
    FAPI-2 is a quinoline-based fibroblast activation protein (FAP)-targeting ligand that can be labeled as 68Ga-FAPI-2 and used as a PET tracer for cancer diagnosis. FAPI-2 has advantages such as fast tracer kinetics, no need for fasting preparation, and being unaffected by blood glucose .
    FAPI-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: